ClinicalTrials.gg
Not yet recruitingNCT06251804Updated Feb 13, 2024

Effectiveness of Short-Foot Exercises in Water and on Land in Pes Planus

An interventional study of Water exercise program and Land-based-program in Pes Planus, sponsored by Istanbul Medipol University Hospital. Not yet recruiting at 1 site in Turkey. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

Pes planus is caused by the elongation of the intrinsic muscles in the medial arch of the foot, causing the arch to approach the ground or the sole of the foot to touch the ground completely.

Read the detailed description

For this purpose, in this project, the effectiveness of short foot exercises in water and on land will be compared in young adults with pes planus.

02

Conditions studied

  • Pes Planus

Browse trials for

03

In context

Flatfoot

173 studies on the registry are indexed under Flatfoot; 44 are open to participants now.

This study's planned enrollment of 50 is above the median of 40 across 122 interventional studies indexed under Flatfoot.

Browse Flatfoot studies →

Lead sponsor

Istanbul Medipol University Hospital is the lead sponsor of 366 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18-25
  • Having bilateral pes planus
  • People with a score of 6 and above on the Foot Posture Index Score
  • Individuals with more than 10 millimeters of pronation according to the navicular drop test were included.

Exclusion criteria

Exclusion Criteria:

  • Rigid pes planus, hallux valgus, hallux rigidus, epin calcanei
  • Lower extremity surgery
  • Neurological or orthopedic problems and history of disease
  • Regular exercise for the treatment of pes planus in the last three months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Water exercise program

    The treatment program includes in-water exercise program. Participants will be exercised twice a week for six weeks.

    Other: Water exercise program

  • Active comparator
    Land-based-program

    The treatment program includes land-based exercise program. Participants will be exercised twice a week for six weeks.

    Other: Land-based-program

Interventions

  • OtherWater exercise program

    The exercise program includes a short foot exercise and will be given in water.

  • OtherLand-based-program

    The exercise program includes a short foot exercise and will be given on land.

06

What researchers measure

Primary outcomes

  1. Foot Posture Index

    A widely used method to assess foot posture and classify individuals according to different foot types. Each criterion is scored on a 5-point scale ranging from -2 to +2.

    Time frame: 6 weeks

  2. Navicular Drop Test

    It is a clinical assessment used to evaluate the degree of foot pronation or flattening of the medial longitudinal arch during weight bearing. It is commonly used to assess foot pronation, especially the vertical displacement of the navicular bone during weight bearing.

    Time frame: 6 weeks

  3. Biodex Balance System

    It is a computerized balance assessment system widely used in clinical and research settings to assess and improve balance and stability. The Biodex Balance System typically consists of a computerized platform with force sensors, visual feedback display and various training modes. It provides quantitative measurements of balance parameters, allowing accurate assessment and monitoring of progress

    Time frame: 6 weeks

Secondary outcomes

  1. Pittsburg Sleep Index

    It is a widely used scale that evaluates sleep quality and disorders related to sleep problems. The Pitssburg sleep index includes 19 questions Each question is scored from 0 to 3 points, with a high score indicating poor sleep quality. The scale has a total score with a minimum score of 0 and a maximum score of 21 points

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Apr 2024, 2 months later.

Of 89 non-industry interventional studies with no phase under Flatfoot, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 2 months is below that.

Counting every sponsor, half of 89 studies reached it within 7 months; a quarter within 2 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 9, 2024
StartEst.
Feb 15, 2024
Primary completionEst.
Apr 15, 2024
CompletionEst.
Jul 10, 2024
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06251804
Responsible party
hazal genc (Principal Investigator, Istanbul Medipol University Hospital) — Principal investigator
First posted
Feb 9, 2024
Start date
Feb 15, 2024 (estimated)
Primary completion
Apr 15, 2024 (estimated)
Completion
Jul 10, 2024 (estimated)
Last update
Feb 13, 2024

Study contacts

Hazal GENÇ, PhD
Contact
hazaloksuz@gmail.com
+905413204291
Mustafa Emre Kıyık
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion